SANTA FE, NEW MEX. – February 22, 2024 – State Representative Joy Garratt was honored with the ‘Legislative Champion Award’ by the American Cancer Society Cancer Action Network (ACS CAN) during a luncheon, Thursday. This award is the highest honor given by the organization. Garratt was recognized for her leading role in expanding access to biomarker testing in New Mexico. She served as a lead sponsor for HB 73 during the 2023 legislative session.
Senate Votes to Remove Barriers to Precision Treatments
Cancer Advocates Urge the House to Follow the Senate’s Lead Ensuring Hoosiers Have Better Access to Personalized Care.
INDIANAPOLIS, IN – This afternoon, the Indiana Senate passed Senate Bill 273, which would ensure biomarker testing, a game changer in the fight against cancer and an essential step in accessing precision medicine treatments, is covered by more insurance plans in the Hoosier state.
The following is a statement from Allie Kast, government relations director for the American Cancer Society Cancer Action Network (ACS CAN) in Indiana:
"Biomarker testing and precision medicine are helping extend and improve lives by tailoring care and treatment to a person’s specific type of cancer. Over the past few months, we have heard countless stories of the difficulties patients face in attempting to access this critical testing. It’s time for that to change.
"This legislation will help address a significant barrier and bring the promise of precision medicine to more Hoosiers no matter their income or where they live. This can provide many benefits to patients, including better outcomes, improved quality of life, and, in some cases, reduced costs from bypassing ineffective therapies.
"ACS CAN thanks Senators Ed Charbonneau and Vaneta Becker, and our several coauthors, for championing this effort and the Indiana Senate for approving this legislation. We urge the House to quickly follow suit and take this significant step towards improving health outcomes and lowering health care costs."
In 2024, approximately 14,280 Hoosiers will die from cancer. Improved access to biomarker testing can connect more patients to the most effective treatments, enabling more patients to live longer and have a better chance of beating cancer.
For more information on precision medicine, cancer biomarkers, current barriers to biomarker testing and ACS CAN’s policy recommendations, visit www.fightcancer.org/biomarkers.
About ACS CAN
The American Cancer Society Cancer Action Network (ACS CAN) makes cancer a top priority for policymakers at every level of government. ACS CAN empowers volunteers across the country to make their voices heard to influence evidence-based public policy change that improves the lives of people with cancer and their families. We believe everyone should have a fair and just opportunity to prevent, find, treat, and survive cancer. Since 2001, as the American Cancer Society’s nonprofit, nonpartisan advocacy affiliate, ACS CAN has successfully advocated for billions of dollars in cancer research funding, expanded access to quality, affordable health care, and advanced proven tobacco control measures. We’re more determined than ever to stand together with our volunteers to end cancer as we know it, for everyone. Join the fight by visiting www.fightcancer.org.